Given its resilient business model, strong cash flows, and significant domestic and international growth opportunities, Dollarama remains well-positioned to deliver healthy long-term returns.
Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial.
Th
FOX (NASDAQ:FOX) reported fiscal third-quarter revenue of $4 billion and adjusted EBITDA of $954 million, up 11% from a year earlier, as executives said distribution revenue growth, Fox News advertising strength and digital momentum helped offset the absence of last year’s Super Bowl broadcast.
Exe
Cronos Group (NASDAQ:CRON) reported record first-quarter 2026 net revenue and gross profit, with management pointing to growth in Israel, gains for its Spinach brand in Canada and continued international expansion as key drivers of the quarter.
Chairman, President and CEO Mike Gorenstein said Crono
Ceva (NASDAQ:CEVA) reported an 11% year-over-year increase in first-quarter 2026 revenue, driven by its strongest licensing quarter in three years and new design wins across Bluetooth, satellite communications, ultra-wideband, Wi-Fi and edge AI.
Chief Executive Officer Amir Panush said the company
Aurubis (ETR:NDA) reported a stronger second quarter in its 2025/2026 fiscal year and raised its full-year earnings outlook, citing high metal prices, improving recycling markets, healthy copper product demand and stronger sulfuric acid markets.
Chief Executive Officer Toralf Haag said operating ea
Exp World (NASDAQ:AGNT) reported improved first-quarter profitability metrics and reiterated its full-year 2026 outlook, while management emphasized its recent NextHome acquisition, international growth and investments in agent-focused technology and personal development offerings.
Jesse Hill, CFO
ARKO Petroleum Corp. reported stronger first-quarter 2026 results, with management pointing to fuel-margin discipline, wholesale growth and the company’s post-IPO balance sheet as key factors supporting its outlook.
Chairman, President and Chief Executive Officer Arie Kotler said adjusted EBITDA ro
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering.
On the company’s fir
Certara (NASDAQ:CERT) reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a strategic reset under Chief Executive Officer Jon Resnick.
Resnick, who said he has passed the 10
GEA Group Aktiengesellschaft (ETR:G1A) reported a stronger first quarter for fiscal 2026, with management saying order intake, sales and profitability improved under the company’s new organizational structure that took effect Jan. 1.
CEO Stefan Klebert said the company booked EUR 1.5 billion in ord
